Real-world treatment practices for EGFR-mutant NSCLC patients

The introduction of tyrosine kinase inhibitors (TKIs) targeting mutant epidermal growth factor receptor (EGFR) has revolutionized the treatment of patients with EGFR-mutant advanced NSCLC. In the recently published REVEAL trial, investigators assessed the current clinical practice for these patients in Belgium revealing some striking observations. In fact, one out of five EGFR-mutant advanced NSCLC patients in this study did not receive ESMO standard of care in first line. After progression on a first EGFR-TKI, Moreover, nearly 30% of patients were not tested for the presence of a T790M mutation after progression on first-line treatment with an EGFR TKI and a quarter of patients did not receive subsequent systemic treatment for NSCLC. These findings underscore the need for more diligent decision-making in the treatment of these patients in order to maximize the clinical potential of EGFR TKIs.